What is the 13F Pro Quality Score for DNLI?

13F Pro ranks Denali Therapeutics Inc. (DNLI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DNLI's current score at https://13fpro.ai/research/DNLI (free sign-up required for the full ranking).

Which hedge funds own the most DNLI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DNLI include BlackRock,, BAILLIE GIFFORD & CO, Temasek Holdings (Private) Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DNLI as soon as new 13F filings post.

Where does 13F Pro source DNLI data?

All Denali Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Denali Therapeutics Inc. files with the SEC under CIK 1714899. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DNLI in?

Denali Therapeutics Inc. (DNLI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DNLI research updated on 13F Pro?

DNLI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Denali Therapeutics Inc.(DNLI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1714899 DNLI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

DNLI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Denali Therapeutics Inc. (DNLI), a Healthcare sector company. DNLI is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Denali Therapeutics Inc. reports net income of $-128.4M, free cash flow of $-133.7M. Top institutional holders of DNLI by reported 13-F value include BlackRock,, BAILLIE GIFFORD & CO, Temasek Holdings (Private) Ltd, based on the most recent SEC filings. DNLI trades on the Nasdaq exchange and files with the SEC under CIK 1714899. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DNLI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Denali Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-128.4M

Free Cash Flow

Q1 2026

$-133.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2024

FY18 $129.2MFY20 $335.7MFY22 $108.5MFY24 $0.00

Net Income

-29.7% YoY

$-422.8MFY 2024

FY18 $-36.2MFY20 $71.1MFY22 $-326.0MFY24 $-422.8M

Operating Income

-43.0% YoY

$-487.3MFY 2024

FY18 $-46.4MFY20 $62.7MFY22 $-340.7MFY24 $-487.3M

EPS (Diluted)

+1.2% YoY

$-2.57FY 2024

FY18 $-0.39FY20 $0.63FY22 $-2.60FY24 $-2.57

Total Assets

-5.9% YoY

$1.37BFY 2024

FY18 $662.0MFY20 $1.60BFY22 $1.46BFY24 $1.37B

Op. Cash Flow

-42.1% YoY

$-347.7MFY 2024

FY18 $50.1MFY20 $416.2MFY22 $-244.7MFY24 $-347.7M

Metric	FY 2024	FY 2022	FY 2020	FY 2018	FY 2017	FY 2016
Revenue	$0.00 -100.0%	$108.5M -67.7%	$335.7M +159.9%	$129.2M	$0.00	$0.00
Net Income	$-422.8M -29.7%	$-326.0M -558.3%	$71.1M +296.3%	$-36.2M +58.9%	$-88.2M -1.8%	$-86.7M
Operating Income	$-487.3M -43.0%	$-340.7M -643.3%	$62.7M +235.2%	$-46.4M +48.6%	$-90.1M -3.1%	$-87.4M
EPS (Diluted)	$-2.57 +1.2%	$-2.60 -512.7%	$0.63 +261.5%	$-0.39	—	—
Total Assets	$1.37B -5.9%	$1.46B -9.0%	$1.60B +142.3%	$662.0M +36.0%	$486.7M	—
Operating Cash Flow	$-347.7M -42.1%	$-244.7M -158.8%	$416.2M +730.4%	$50.1M +165.4%	$-76.6M -6.6%	$-71.9M

AI Insight: DNLI Financial Trends

Denali's cash burn rate remains elevated at ~$130M quarterly with equity declining 33% from $1,387M to $926M over two years.

• Operating losses stabilized around $137M quarterly since Q4 2025 after worsening from $117M in Q2 2024.

• Net losses fluctuated between $124M-$133M in recent quarters, showing no clear improvement trajectory.

• Equity declined steadily from $1,387M in Q2 2024 to $926M in Q1 2026.

⚠ Operating cash flow burn accelerated to $131M in Q1 2026, matching the peak from Q1 2025.

⚠ Runway concerns as equity base shrinks with sustained quarterly cash consumption exceeding $100M.

AI Insight: DNLI Ratio Trends

Denali's profitability metrics deteriorated sharply, with ROE declining from -28.6% in Q2 2024 to -55.5% in Q1 2026.

• ROE worsened from -28.6% in Q2 2024 to -55.5% in Q1 2026, nearly doubling losses.

• ROIC declined from -33.6% in Q2 2024 to -59.3% in Q1 2026, indicating deteriorating capital efficiency.

• ROA fell from -26.4% in Q2 2024 to -40.6% in Q1 2026, showing weakening asset productivity.

⚠ Consistent quarterly deterioration across all profitability metrics with no signs of stabilization through Q1 2026.

⚠ Missing operating margin and net profit margin data limits visibility into operational efficiency trends.

Get alerted when DNLI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Denali Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DNLI

BlackRock, Inc.
$250.3M13,034,434 sh
BAILLIE GIFFORD & CO
$231.7M12,066,479 sh
Temasek Holdings (Private) Ltd
$134.6M7,012,974 sh
STATE STREET CORP
$120.4M6,272,001 sh
VANGUARD CAPITAL MANAGEMENT LLC
$118.0M6,147,957 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$117.5M6,120,160 sh
FMR LLC
$87.8M4,575,374 sh
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$85.1M4,432,314 sh
GOLDMAN SACHS GROUP INC
$84.6M4,407,255 sh
BAKER BROS. ADVISORS LP
$71.6M3,731,695 sh

Fund	Value	Shares
BlackRock, Inc.	$250.3M	13,034,434
BAILLIE GIFFORD & CO	$231.7M	12,066,479
Temasek Holdings (Private) Ltd	$134.6M	7,012,974
STATE STREET CORP	$120.4M	6,272,001
VANGUARD CAPITAL MANAGEMENT LLC	$118.0M	6,147,957
VANGUARD PORTFOLIO MANAGEMENT LLC	$117.5M	6,120,160
FMR LLC	$87.8M	4,575,374
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME	$85.1M	4,432,314
GOLDMAN SACHS GROUP INC	$84.6M	4,407,255
BAKER BROS. ADVISORS LP	$71.6M	3,731,695

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DNLI on your watchlist

Track score changes the day Denali Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DNLI a good stock to buy?

13F Pro's AI-powered analysis of Denali Therapeutics Inc. (DNLI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DNLI are available on the DNLI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DNLI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DNLI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Denali Therapeutics Inc.'s investment landscape.